Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pyroglutamyl-peptidase I (PGPEP1) is a cytosolic cysteine protease belonging to the peptidase C15 family, found in humans and widely across species. This enzyme selectively cleaves N-terminal pyroglutamate (pGlu) residues from bioactive peptides and proteins, including several hypothalamic hormones such as thyrotropin-releasing hormone (TRH) and luteinizing hormone-releasing hormone (LH-RH), which are otherwise resistant to degradation by conventional aminopeptidases. By regulating the removal of pGlu residues, Pyroglutamyl-peptidase I plays a role in hormone inactivation, peptide turnover, and potentially nutrient assimilation, primarily in lower organisms. The enzyme is characterized by a catalytic triad (Cys-His-Asp/Glu) and does not conform to the typical oxyanion hole seen in many cysteine proteases. Its expression and activity are altered in various disease conditions, and it is being studied for roles in cancer biology and male infertility as well as a general marker of peptide metabolism.
Proteolytic removal of N-terminal pyroglutamyl residue via catalytic triad (Cys-His-Asp/Glu)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pyroglutamyl-peptidase I (PGPEP1).